Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 283-291

  Hemeryck, Alex ^b   Lefebvre, Romain A ^b   De Vriendt, Cindy ^b   Belpaire, Frans M ^a  

^a GHENT UNIVERSITY   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; METOPROLOL TARTRATE; PAROXETINE;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; GASTROINTESTINAL SYMPTOM; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SOMNOLENCE; STEREOCHEMISTRY;

EID: 0008803827     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104788     Document Type: Article

References (36)

1. 1. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of β-adrenoreceptor antagonists: clinical pharmacokinetic considerations. Clin Pharmacokinet 1986;11:1-17.
2. 3) in man, the dog and the rat. Acta Pharmacol Toxicol 1975;36(suppl V):125-35.
3. 3. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988;247:242-7.
4. 4. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996;24:350-5.
5. 5. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther 1983;34:732-7.
6. 6. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors; part II. J Clin Psychopharmacol 1996; 16:345-55.
7. 7. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998;54: 261-4.
8. 8. König F, Häfele M, Hauger B, Löble M, Wössner S, Wolfersdorf M. Bradycardie nach Therapiebeginn mit Metoprolol und Paroxetin. Psychiatr Prax 1996;23: 244-5.
9. 9. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993; 341:967-8.
10. 10. Mourilhe P, Stokes PE. Risks and benefits of selective serotonin reuptake inhibitors in treatment of depression. Drug Saf 1998;18:57-82.
11. 11. Hein MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 1991;206:173-83.
12. 12. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5: 215-23.
13. 13. Vermeulen AM, Belpaire FM, De Smet F, Vercruysse I, Bogaert MG. Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. J Gerontol 1993;48:B108-B114.
14. 14. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism: population and family studies. Br J Clin Pharmacol 1985;20:555-66.
15. 15. Lücker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990;30:S17-S27.
16. 16. Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheridge RC, Jorkasky DK. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 1997;17: 451-9.
17. 17. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
18. 18. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994;27: 307-30.
19. 19. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17:284-91.
20. 20. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
21. 21. Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62:334-47.
22. 22. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-411.
23. 23. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
24. 24. Leemann T, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 1986;29:739-41.
25. 25. Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine or sertraline. J Clin Psychopharmacol 1999;19:155-63.
26. 26. Kendall MJ, John VA, Quarterman CP, Welling PQ. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metoprolol. Eur J Clin Pharmacol 1980;17:87-92.
27. 27. Lennard MS. The polymorphic oxidation of beta-adrenoreceptor antagonists. Pharmacol Ther 1989;41: 461-77.
28. 28. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
29. 29. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-34.
30. 30. Van Harten J. Clinical pharmacokinetics of selective serotonin re-uptake inhibitors. Clin Pharmacokinet 1993;24: 203-20.
31. 31. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995;39:421-32.
32. 32. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
33. 33. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine, paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
34. 34. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-68.
35. 35. Lennard MS, Lewis RV, Brawn LA, Tucker GT, Ramsay LE, Jackson PR, et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 1989;27:429-34.
36. 36. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611-3.